thalidomide has been researched along with Crow-Fukase Syndrome in 76 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adults (age ≥20 years) with POEMS syndrome who were ineligible for autotransplantation were randomly assigned (1:1) by a minimisation method to treatment with oral dexamethasone (12 mg/m(2) per day on the first 4 days of every 28-day cycle) plus either oral thalidomide (200 mg daily) or placebo for six cycles." | 9.22 | Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. ( Aoyagi, R; Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kawachi, I; Kikuchi, S; Kira, J; Kohara, N; Koike, H; Kusunoki, S; Kuwabara, S; Misawa, S; Mitsui, Y; Nagashima, K; Nakashima, I; Nishizawa, M; Sasaki, H; Sato, Y; Sekiguchi, Y; Sobue, G; Takashima, H; Watanabe, O; Yabe, I, 2016) |
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 9.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| "The purpose of this pooled analysis was to synthesize all available data so as to evaluate the efficacy and safety of lenalidomide in patients with POEMS syndrome." | 8.90 | Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. ( Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Psaltopoulou, T; Sergentanis, TN; Terpos, E; Zagouri, F, 2014) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Eosinophilia has rarely been described with lenalidomide." | 7.88 | Eosinophilia secondary to lenalidomide therapy. ( Collado-Borrell, R; Escudero-Vilaplana, V; González-Arias, E; Osorio-Prendes, S; Sanjurjo-Sáez, M, 2018) |
| "Thirty-five patients with newly diagnosed POEMS syndrome were treated with Lenalidomide (10 mg daily for 21 days) and dexamethasone (40 mg once per week) for 12 cycles." | 7.83 | Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone. ( Cai, Q; Cao, X; Huang, X; Li, J; Wang, C; Yang, H; Zhou, D, 2016) |
| "A 60-year-old male with POEMS syndrome received lenalidomide and high-dose dexamethasone combination therapy as an initial treatment, with no severe adverse events occurring during the treatment." | 7.78 | [POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy]. ( Fujisawa, S; Fujita, H; Imai, N; Ishigatsubo, Y; Matsuura, S; Ogusa, E; Taguchi, J; Tomita, N, 2012) |
| "This study was purposed to analyze the clinical features and evaluate the efficacy of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)." | 7.78 | [Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)]. ( Gan, SL; Liu, YF; Meng, XL; Sun, H; Sun, L; Wan, DM; Zhou, JW, 2012) |
| "Thalidomide treatment should be further studied as a treatment for POEMS syndrome, particularly for patients who are not indicated for transplantation therapy." | 7.74 | Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. ( Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakaseko, C; Nishimura, M; Sawai, S, 2008) |
| "POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis." | 6.58 | Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. ( Autore, F; Bacigalupo, A; Chiusolo, P; Innocenti, I; Laurenti, L; Luigetti, M; Piccirillo, N; Sica, S; Sora, F, 2018) |
| "The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms." | 6.44 | [New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008) |
| "POEMS syndrome is associated with plasma cell dyscrasias and upregulation of vascular endothelial growth factor leading to systemic oedema, papilloedema and pulmonary hypertension." | 5.48 | POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation. ( Gilbert, L; Ordway, S; Wanko, S, 2018) |
| " In conclusion, low-dose lenalidomide plus dexamethasone therapy is an effective and safe regimen for patients with relapsed or refractory POEMS syndrome." | 5.42 | Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. ( Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB, 2015) |
| "POEMS syndrome is a rare disorder characterized by polyneuropathy, monoclonal gammopathy, multiorgan involvement, and elevated vascular endothelial growth factor levels." | 5.39 | Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. ( Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C, 2013) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 5.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "A POEMS syndrome is a rare disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities including hyperpigmentation and hypertrichosis." | 5.36 | Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. ( Hata, H; Kawano, Y; Kimura, E; Maruyoshi, N; Mitsuya, H; Nakama, T; Uchino, M, 2010) |
| " Adults (age ≥20 years) with POEMS syndrome who were ineligible for autotransplantation were randomly assigned (1:1) by a minimisation method to treatment with oral dexamethasone (12 mg/m(2) per day on the first 4 days of every 28-day cycle) plus either oral thalidomide (200 mg daily) or placebo for six cycles." | 5.22 | Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. ( Aoyagi, R; Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kawachi, I; Kikuchi, S; Kira, J; Kohara, N; Koike, H; Kusunoki, S; Kuwabara, S; Misawa, S; Mitsui, Y; Nagashima, K; Nakashima, I; Nishizawa, M; Sasaki, H; Sato, Y; Sekiguchi, Y; Sobue, G; Takashima, H; Watanabe, O; Yabe, I, 2016) |
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 5.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| "The purpose of this pooled analysis was to synthesize all available data so as to evaluate the efficacy and safety of lenalidomide in patients with POEMS syndrome." | 4.90 | Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. ( Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Psaltopoulou, T; Sergentanis, TN; Terpos, E; Zagouri, F, 2014) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Eosinophilia has rarely been described with lenalidomide." | 3.88 | Eosinophilia secondary to lenalidomide therapy. ( Collado-Borrell, R; Escudero-Vilaplana, V; González-Arias, E; Osorio-Prendes, S; Sanjurjo-Sáez, M, 2018) |
| "Thirty-five patients with newly diagnosed POEMS syndrome were treated with Lenalidomide (10 mg daily for 21 days) and dexamethasone (40 mg once per week) for 12 cycles." | 3.83 | Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone. ( Cai, Q; Cao, X; Huang, X; Li, J; Wang, C; Yang, H; Zhou, D, 2016) |
| "This study was purposed to analyze the clinical features and evaluate the efficacy of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)." | 3.78 | [Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)]. ( Gan, SL; Liu, YF; Meng, XL; Sun, H; Sun, L; Wan, DM; Zhou, JW, 2012) |
| " High-dose chemotherapy with auto-peripheral blood stem cell transplantation (ASCT) and thalidomide, which are new therapeutic approaches to POEMS syndrome could salvage lots of patients with POEMS syndrome and substantially improve the prognosis." | 3.78 | [Treatment for POEMS syndrome: the current status and tasks for the future]. ( Misawa, S, 2012) |
| "A 60-year-old male with POEMS syndrome received lenalidomide and high-dose dexamethasone combination therapy as an initial treatment, with no severe adverse events occurring during the treatment." | 3.78 | [POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy]. ( Fujisawa, S; Fujita, H; Imai, N; Ishigatsubo, Y; Matsuura, S; Ogusa, E; Taguchi, J; Tomita, N, 2012) |
| "Thalidomide treatment should be further studied as a treatment for POEMS syndrome, particularly for patients who are not indicated for transplantation therapy." | 3.74 | Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. ( Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakaseko, C; Nishimura, M; Sawai, S, 2008) |
| "The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria." | 2.61 | POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. ( Dispenzieri, A, 2019) |
| "POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis." | 2.58 | Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. ( Autore, F; Bacigalupo, A; Chiusolo, P; Innocenti, I; Laurenti, L; Luigetti, M; Piccirillo, N; Sica, S; Sora, F, 2018) |
| "POEMS syndrome is potentially fatal disease, and patients' quality of life deteriorates because of progressive neuropathy and/or massive peripheral edema or pleural effusion/ascites." | 2.49 | [Crow-Fukase (POEMS) syndrome: pathophysiology and treatments]. ( Kuwabara, S, 2013) |
| "POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes." | 2.49 | New advances in the diagnosis and treatment of POEMS syndrome. ( Li, J; Zhou, DB, 2013) |
| "The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytomas, is likely to be responsible for most of the characteristic symptoms." | 2.48 | Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. ( Arimura, K; Dispenzieri, A; Kuwabara, S; Misawa, S; Nakaseko, C, 2012) |
| "Systematic search for monoclonal gammopathy by immunofixation and serum free light chains is very useful for the management of progressive peripheral neuropathies of unknown origin." | 2.47 | [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. ( Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M, 2011) |
| "The pathogenesis of POEMS syndrome is not well understood; however overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of the characteristic symptoms, including neuropathy." | 2.44 | [Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]. ( Misawa, S, 2008) |
| "The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms." | 2.44 | [New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008) |
| "POEMS syndrome is associated with plasma cell dyscrasias and upregulation of vascular endothelial growth factor leading to systemic oedema, papilloedema and pulmonary hypertension." | 1.48 | POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation. ( Gilbert, L; Ordway, S; Wanko, S, 2018) |
| "She developed transient ischemic attack after the introduction of lenalidomide plus dexamethasone (Rd) therapy despite no vascular risk factors." | 1.48 | Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( Hashida, H; Hatano, K; Irie, K; Matsumoto, H; Mitsutake, A; Tsukada, N, 2018) |
| "Lenalidomide therapy was started after the diagnosis and the patient had a favorable outcome." | 1.46 | Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: A case report. ( Akiyama, H; Hara, D; Hasegawa, Y; Hoshikawa, M; Nukui, S; Shimizu, T, 2017) |
| "Twenty-seven (67." | 1.46 | OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME. ( Cai, H; Cai, QQ; Cao, XX; Dai, RP; Huang, XF; Li, J; Zhang, X; Zhou, DB, 2017) |
| " In conclusion, low-dose lenalidomide plus dexamethasone therapy is an effective and safe regimen for patients with relapsed or refractory POEMS syndrome." | 1.42 | Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. ( Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB, 2015) |
| "If patients have optic disc edema in both eyes with no intracranial space-occupying lesion, POEMS syndrome should be considered in differential diagnosis, regardless of age." | 1.40 | POEMS syndrome in a 20-year-old patient diagnosed following a complaint of reduced visual acuity. ( Doi, S; Hosogi, M; Hosokawa, M; Kawata, T; Kimura, S; Kondo, E; Morizane, Y; Shiode, Y; Shiraga, F, 2014) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| "POEMS syndrome is a rare disorder characterized by polyneuropathy, monoclonal gammopathy, multiorgan involvement, and elevated vascular endothelial growth factor levels." | 1.39 | Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. ( Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C, 2013) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 1.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "A POEMS syndrome is a rare disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities including hyperpigmentation and hypertrichosis." | 1.36 | Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. ( Hata, H; Kawano, Y; Kimura, E; Maruyoshi, N; Mitsuya, H; Nakama, T; Uchino, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (15.79) | 29.6817 |
| 2010's | 58 (76.32) | 24.3611 |
| 2020's | 6 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, S | 1 |
| Huang, L | 1 |
| Fan, W | 1 |
| Liang, D | 1 |
| Zhu, X | 1 |
| Jiang, S | 1 |
| Ge, Y | 1 |
| Oyama, T | 1 |
| Taoka, K | 1 |
| Chiba, A | 1 |
| Masamoto, Y | 1 |
| Ikemura, M | 1 |
| Honda, A | 1 |
| Maki, H | 1 |
| Kurokawa, M | 1 |
| Vaxman, I | 1 |
| Kumar, SK | 1 |
| Buadi, F | 1 |
| Lacy, MQ | 1 |
| Dingli, D | 1 |
| Hayman, S | 1 |
| Kourelis, T | 1 |
| Warsame, R | 1 |
| Hwa, Y | 1 |
| Fonder, A | 1 |
| Hobbs, M | 1 |
| Muchtar, E | 1 |
| Leung, N | 1 |
| Kapoor, P | 1 |
| Go, R | 1 |
| Lin, Y | 1 |
| Gonsalves, W | 1 |
| Siddiqui, M | 1 |
| Kyle, RA | 1 |
| Rajkumar, SV | 1 |
| Gertz, MA | 1 |
| Dispenzieri, A | 4 |
| Fujii, T | 1 |
| Ohno, N | 1 |
| Sakamoto, N | 1 |
| Matsui, T | 1 |
| Sahara, N | 1 |
| Matsunaga, T | 1 |
| Suichi, T | 1 |
| Misawa, S | 12 |
| Nagashima, K | 2 |
| Sato, Y | 4 |
| Iwai, Y | 2 |
| Katayama, K | 4 |
| Sekiguchi, Y | 3 |
| Shibuya, K | 3 |
| Amino, H | 2 |
| Suzuki, YI | 1 |
| Tsuneyama, A | 1 |
| Nakamura, K | 1 |
| Kuwabara, S | 19 |
| Lomas, OC | 1 |
| Streetly, M | 1 |
| Pratt, G | 1 |
| Cavet, J | 1 |
| Royston, D | 1 |
| Schey, S | 1 |
| Ramasamy, K | 1 |
| Al-Mayoof, O | 1 |
| Al Sughaiyer, H | 1 |
| Abuomar, W | 1 |
| Khan, M | 1 |
| Escudero-Vilaplana, V | 1 |
| Osorio-Prendes, S | 1 |
| Collado-Borrell, R | 1 |
| González-Arias, E | 1 |
| Sanjurjo-Sáez, M | 1 |
| Autore, F | 1 |
| Innocenti, I | 1 |
| Luigetti, M | 2 |
| Piccirillo, N | 1 |
| Sora, F | 2 |
| Chiusolo, P | 2 |
| Sica, S | 2 |
| Bacigalupo, A | 1 |
| Laurenti, L | 2 |
| Hara, D | 1 |
| Akiyama, H | 1 |
| Nukui, S | 1 |
| Shimizu, T | 1 |
| Hoshikawa, M | 1 |
| Hasegawa, Y | 1 |
| Nozza, A | 1 |
| Terenghi, F | 1 |
| Gallia, F | 1 |
| Adami, F | 2 |
| Briani, C | 2 |
| Merlini, G | 1 |
| Giordano, L | 1 |
| Santoro, A | 1 |
| Nobile-Orazio, E | 1 |
| Zaidi, S | 1 |
| Sattar, S | 1 |
| Asumal, KB | 1 |
| Gremain, V | 1 |
| Litrowski, N | 1 |
| Boulard, C | 1 |
| Marguet, F | 1 |
| Courville, P | 1 |
| Zarnitsky, C | 1 |
| Langlois, V | 1 |
| Jaccard, A | 3 |
| Mitsutake, A | 1 |
| Matsumoto, H | 1 |
| Hatano, K | 1 |
| Irie, K | 1 |
| Tsukada, N | 1 |
| Hashida, H | 1 |
| Ordway, S | 1 |
| Gilbert, L | 1 |
| Wanko, S | 1 |
| Keddie, S | 1 |
| D'Sa, S | 1 |
| Lunn, MP | 1 |
| Yokouchi, H | 2 |
| Baba, T | 2 |
| Oshitari, T | 2 |
| Yamamoto, S | 2 |
| Grandoni, F | 1 |
| Stalder, G | 1 |
| Borgeat Kaeser, A | 1 |
| Ribi, C | 1 |
| Cairoli, A | 1 |
| Blum, S | 1 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Ohashi, K | 1 |
| Yokoyama, A | 1 |
| Kagoo, T | 1 |
| Hosoda, T | 1 |
| Yamamoto, R | 1 |
| Yoneda, M | 1 |
| Kudo, M | 1 |
| Boku, S | 1 |
| Ueno, H | 1 |
| Yano, T | 1 |
| Zagouri, F | 1 |
| Kastritis, E | 1 |
| Gavriatopoulou, M | 1 |
| Sergentanis, TN | 1 |
| Psaltopoulou, T | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Wu, KL | 1 |
| Chen, HW | 1 |
| Lin, SH | 1 |
| Chen, JS | 1 |
| Lestang, E | 1 |
| Caristan, A | 1 |
| Néel, A | 1 |
| Graveleau, J | 1 |
| Duhamel, E | 1 |
| Masseau, A | 1 |
| Connault, J | 1 |
| Maisonneuve, H | 1 |
| Le Gouill, S | 1 |
| Blin, N | 1 |
| Touzeau, C | 1 |
| Moreau, P | 1 |
| Hamidou, M | 1 |
| Cai, QQ | 3 |
| Wang, C | 3 |
| Cao, XX | 2 |
| Cai, H | 2 |
| Zhou, DB | 4 |
| Li, J | 5 |
| Doi, S | 1 |
| Kimura, S | 1 |
| Morizane, Y | 1 |
| Hosogi, M | 1 |
| Hosokawa, M | 1 |
| Shiode, Y | 1 |
| Kawata, T | 1 |
| Kondo, E | 1 |
| Shiraga, F | 1 |
| Sobue, G | 2 |
| Yabe, I | 2 |
| Watanabe, O | 2 |
| Nishizawa, M | 2 |
| Kusunoki, S | 2 |
| Kikuchi, S | 2 |
| Nakashima, I | 2 |
| Ikeda, S | 2 |
| Kohara, N | 2 |
| Kanda, T | 2 |
| Kira, J | 3 |
| Hanaoka, H | 3 |
| Sawai, S | 3 |
| Beppu, M | 3 |
| Nomura, F | 2 |
| Watanabe, K | 1 |
| Ohwada, C | 2 |
| Takeuchi, M | 2 |
| Sakaida, E | 2 |
| Nakaseko, C | 6 |
| Robey, RC | 1 |
| Campus, C | 1 |
| Ringuette, B | 1 |
| Shumate, M | 1 |
| Guan, YZ | 1 |
| Su, W | 1 |
| Yang, H | 1 |
| Huang, X | 1 |
| Cai, Q | 1 |
| Cao, X | 1 |
| Zhou, D | 1 |
| Magy, L | 1 |
| Aoyagi, R | 1 |
| Koike, H | 1 |
| Sasaki, H | 1 |
| Takashima, H | 1 |
| Kawachi, I | 1 |
| Mitsui, Y | 1 |
| Zhang, X | 1 |
| Huang, XF | 1 |
| Dai, RP | 1 |
| Kawamura, N | 1 |
| Sakai, S | 1 |
| Takeda, Y | 1 |
| Abe, D | 1 |
| Masuda, S | 1 |
| Shimizu, N | 1 |
| Cho, R | 1 |
| Nishimura, M | 2 |
| Kanai, K | 4 |
| Imai, N | 2 |
| Taguchi, J | 2 |
| Yagi, N | 1 |
| Konishi, T | 1 |
| Serizawa, M | 1 |
| Kobari, M | 1 |
| Sethi, S | 1 |
| Tageja, N | 2 |
| Arabi, H | 1 |
| Penumetcha, R | 1 |
| Inoue, D | 1 |
| Kato, A | 1 |
| Tabata, S | 1 |
| Kitai, T | 1 |
| Takiuchi, Y | 1 |
| Kimura, T | 1 |
| Shimoji, S | 1 |
| Mori, M | 2 |
| Nagai, Y | 1 |
| Togami, K | 1 |
| Matsushita, A | 1 |
| Nagai, K | 1 |
| Maruoka, H | 1 |
| Imai, Y | 1 |
| Kawamoto, M | 1 |
| Takahashi, T | 1 |
| Kawano, Y | 1 |
| Nakama, T | 1 |
| Hata, H | 1 |
| Kimura, E | 1 |
| Maruyoshi, N | 1 |
| Uchino, M | 1 |
| Mitsuya, H | 1 |
| Ohguchi, H | 1 |
| Ohba, R | 1 |
| Onishi, Y | 1 |
| Fukuhara, N | 1 |
| Okitsu, Y | 1 |
| Yamamoto, J | 1 |
| Ishizawa, K | 1 |
| Ichinohasama, R | 1 |
| Harigae, H | 1 |
| Adams, D | 1 |
| Lozeron, P | 1 |
| Theaudin, M | 1 |
| Ribrag, V | 1 |
| Bourhis, JH | 1 |
| Lacroix, C | 1 |
| Iwashita, H | 1 |
| Suyanı, E | 1 |
| Yağcı, M | 1 |
| Sucak, GT | 1 |
| Wang, X | 1 |
| Ye, S | 1 |
| Xiong, C | 1 |
| Gao, J | 1 |
| Xiao, C | 1 |
| Xing, X | 1 |
| Tomás, JF | 1 |
| Giraldo, P | 1 |
| Lecumberri, R | 1 |
| Nistal, S | 1 |
| Manara, R | 1 |
| Lessi, F | 1 |
| Citton, V | 1 |
| Zambello, R | 1 |
| Furuta, N | 1 |
| Tashiro, Y | 1 |
| Ikeda, M | 1 |
| Fujita, Y | 1 |
| Okamoto, K | 1 |
| Vannata, B | 1 |
| Balducci, M | 1 |
| Sabatelli, M | 1 |
| Giannotta, C | 1 |
| De Stefano, V | 1 |
| Leone, G | 1 |
| Zhou, JW | 1 |
| Sun, H | 1 |
| Gan, SL | 1 |
| Liu, YF | 1 |
| Sun, L | 1 |
| Wan, DM | 1 |
| Meng, XL | 1 |
| Arimura, K | 1 |
| Yamada, Y | 1 |
| Moriya, J | 1 |
| Sogawa, K | 1 |
| Yamamoto, H | 1 |
| Taniguchi, J | 1 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Krejčí, M | 1 |
| Zahradová, L | 1 |
| Szturz, P | 1 |
| Koukalová, R | 1 |
| Rehák, Z | 1 |
| Nebeský, T | 1 |
| Hájek, R | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
| Matsuura, S | 1 |
| Ogusa, E | 1 |
| Fujita, H | 1 |
| Tomita, N | 1 |
| Ishigatsubo, Y | 1 |
| Fujisawa, S | 1 |
| Royer, B | 1 |
| Merlusca, L | 1 |
| Abraham, J | 1 |
| Musset, L | 1 |
| Haroche, J | 1 |
| Choquet, S | 1 |
| Leleu, X | 1 |
| Sebban, C | 1 |
| Decaux, O | 1 |
| Galicier, L | 1 |
| Roussel, M | 1 |
| Recher, C | 1 |
| Banos, A | 1 |
| Guichard, I | 1 |
| Brisseau, JM | 1 |
| Godmer, P | 1 |
| Hermine, O | 1 |
| Deplanque, G | 1 |
| Facon, T | 1 |
| Asli, B | 1 |
| Leblond, V | 1 |
| Fermand, JP | 1 |
| Marolleau, JP | 1 |
| Sinisalo, M | 1 |
| Hietaharju, A | 1 |
| Sauranen, J | 1 |
| Wirta, O | 1 |
| Kim, SY | 1 |
| Lee, SA | 1 |
| Ryoo, HM | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Bae, SH | 1 |
| Klein, CJ | 1 |
| Mauermann, ML | 1 |
| Kamezaki, K | 1 |
| Nagafuji, K | 1 |
| Hattori, T | 1 |
18 reviews available for thalidomide and Crow-Fukase Syndrome
| Article | Year |
|---|---|
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome.
Topics: Angiogenesis Inhibitors; Biomarkers; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Per | 2018 |
POEMS Syndrome: Therapeutic Options.
Topics: Allografts; Humans; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Radiot | 2018 |
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
Topics: Adrenal Cortex Hormones; Allografts; Bortezomib; Castleman Disease; Diagnosis, Differential; Humans; | 2019 |
[Crow-Fukase (POEMS) syndrome: pathophysiology and treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Hum | 2013 |
[Rapid improvement of fluid retention with lenalidomide plus low-dose dexamethasone for POEMS syndrome relapsed after autologous peripheral blood stem cell transplantation].
Topics: Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; | 2013 |
Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Middle Aged; POEMS | 2014 |
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dia | 2008 |
[Treatment strategy for POEMS syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Com | 2008 |
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Com | 2008 |
[Advances and perspectives in treatment for refractory neuropathies with special reference to immune-mediated neuropathies and Crow-Fukase syndrome].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2010 |
[Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Hum | 2010 |
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Dru | 2011 |
[Crow-Fukase syndrome (POEMS syndrome)].
Topics: Fatal Outcome; Female; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; POEMS | 2011 |
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; | 2010 |
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Topics: Adrenal Cortex Hormones; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; POEMS Syndrome; | 2012 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromo | 2013 |
[POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Diagnosis, Diffe | 2007 |
4 trials available for thalidomide and Crow-Fukase Syndrome
| Article | Year |
|---|---|
Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Topics: Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lenalidomide; Male; M | 2020 |
Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Therapy, Combination; Female; Glucocortico | 2017 |
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Clinical Protocols; Double-Blind Method; Female; Hematologic Agents; Humans; Japan; Male; Mul | 2015 |
Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Double-Blind Method; | 2016 |
54 other studies available for thalidomide and Crow-Fukase Syndrome
| Article | Year |
|---|---|
Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome.
Topics: Adult; Dexamethasone; Endothelial Cells; Humans; Kidney Diseases; Lenalidomide; Middle Aged; POEMS S | 2022 |
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
Topics: Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Plasmacytoma; PO | 2023 |
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomid | 2023 |
[A Case of POEMS Syndrome Treated by Ld Prior to HDCTx Followed by aPBSCT].
Topics: Humans; Male; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide; Transplantati | 2019 |
The management of Castleman disease.
Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Combined Che | 2021 |
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy.
Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Perip | 2017 |
Eosinophilia secondary to lenalidomide therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cyclophosphamide; Dexamethasone; Eosinophi | 2018 |
Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: A case report.
Topics: Arthritis, Rheumatoid; Cell Proliferation; Diagnosis, Differential; Female; Humans; Immunoelectropho | 2017 |
An Adult with Polyneuropathy and Hypogonadism due to Poems Syndrome.
Topics: Adult; Dexamethasone; Female; Humans; Hypogonadism; Melphalan; Paraproteinemias; POEMS Syndrome; Pol | 2017 |
Necrotizing autoimmune myopathy associated with POEMS syndrome report.
Topics: Autoimmune Diseases; Dexamethasone; Electromyography; Humans; Lenalidomide; Male; Middle Aged; Muscu | 2018 |
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Adult; Brain; Brain Infarction; Dexamethasone; Female; Humans; Immunologic Factors; Ischemic Attack, | 2018 |
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combinati | 2018 |
Advances in POEMS treatment and the need to define standardised outcome measures.
Topics: Biomarkers; Humans; Lenalidomide; Melphalan; Outcome Assessment, Health Care; POEMS Syndrome; Thalid | 2019 |
Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Papilledema; POEMS Syndrome | 2020 |
[Skin Changes in POEMS Syndrome].
Topics: Humans; Lenalidomide; POEMS Syndrome; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2019 |
Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Topics: Aged; Biomarkers; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitiv | 2019 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Intractable ascites, changes in serum vascular endothelial growth factor levels and thalidomide treatment in POEMS syndrome.
Topics: Adult; Ascites; Biomarkers; Female; Humans; POEMS Syndrome; Thalidomide; Treatment Outcome; Vascular | 2014 |
Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
Topics: Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combinatio | 2015 |
Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethason | 2015 |
POEMS syndrome in a 20-year-old patient diagnosed following a complaint of reduced visual acuity.
Topics: Adult; Central Serous Chorioretinopathy; Combined Modality Therapy; Dexamethasone; Drug Therapy, Com | 2014 |
Thalidomide reduces choroidal thickness and optic disc edema in a patient with POEMS syndrome.
Topics: Angiogenesis Inhibitors; Choroid Diseases; Female; Humans; Middle Aged; Papilledema; POEMS Syndrome; | 2015 |
[Crow-Fukase (POEMS) syndrome].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Hematopoietic Stem Cell Transplantat | 2015 |
Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged | 2015 |
POEMS syndrome: complex factors contributing to a delayed diagnosis.
Topics: Delayed Diagnosis; Dexamethasone; Diagnosis, Differential; Electromyography; Glucocorticoids; Humans | 2015 |
Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond.
Topics: Adult; Diagnosis, Differential; Disease Progression; Genetic Markers; Genetic Testing; Hematopoietic | 2016 |
Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.
Topics: Adult; Aged; Dexamethasone; Female; Humans; Hypogonadism; Immunologic Factors; Lenalidomide; Male; M | 2016 |
Thalidomide and POEMS syndrome: a cautious step forward.
Topics: Dexamethasone; Humans; POEMS Syndrome; Thalidomide; Vascular Endothelial Growth Factor A | 2016 |
OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; Lenal | 2017 |
Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation.
Topics: Antibiotics, Antineoplastic; Biomarkers; Blood Transfusion, Autologous; Dexamethasone; Diuretics; Do | 2009 |
Relapse of POEMS syndrome without increased level of VEGF.
Topics: Humans; Immunosuppressive Agents; Neural Conduction; Platelet Count; POEMS Syndrome; Recurrence; Tha | 2009 |
Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction.
Topics: Antineoplastic Agents; Female; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; | 2009 |
Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy; Drug Therapy, Combination; Female; Heart Fail | 2010 |
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Immunologic Factors; Lymphocytes; Middle Age | 2010 |
POEMS syndrome, congestive heart failure and thalidomide -food for thought.
Topics: Capillary Leak Syndrome; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Inflammati | 2010 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Middle Ag | 2011 |
Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Gait Disorders, N | 2011 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combinat | 2011 |
[The cutting-edge of medicine; Crow-Fukase (POEMS) syndrome: diagnosis, pathophysiology, and treatments].
Topics: Humans; POEMS Syndrome; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.
Topics: Adult; Aged; Female; Humans; Lenalidomide; Male; Middle Aged; Nervous System Diseases; POEMS Syndrom | 2012 |
[Treatment for Crow-Fukase (POEMS) syndrome].
Topics: Humans; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide | 2011 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; | 2012 |
[A case of POEMS syndrome associated with Waldenström's macroglobulinemia and treated with lenalidomide].
Topics: Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Thalidomide; Waldenstrom Macroglobulinemia | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined | 2012 |
[Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Female; Huma | 2012 |
Multiple angiogenetic factors are upregulated in POEMS syndrome.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Fibrob | 2013 |
[Treatment for POEMS syndrome: the current status and tasks for the future].
Topics: Humans; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide | 2012 |
[POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Ag | 2012 |
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combi | 2013 |
Thalidomide in POEMS syndrome: case report.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Exanthema; Female; Humans; Middle Aged; POEMS Synd | 2004 |
Thalidomide for POEMS syndrome.
Topics: Adult; Anti-Inflammatory Agents; Castleman Disease; Dexamethasone; Female; Humans; Immunosuppressive | 2006 |
Lenalidomide therapy in a patient with POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Black or African American; Diagnosis, Differential; Humans; Interleuki | 2007 |
Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Dr | 2008 |